Free Trial

ResMed (RMD) Earnings Date, Estimates & Call Transcripts

ResMed logo
$237.27 +5.69 (+2.46%)
(As of 12/20/2024 05:45 PM ET)

ResMed Latest Earnings Summary

Actual EPS
(Oct. 24)
$2.20 Beat By $0.17
Consensus EPS
(Oct. 24)
$2.03

ResMed posted Q1 2025 earnings on October 24, 2024, reporting an EPS of $2.20, which beat the consensus estimate of $2.03 by $0.17. Quarterly revenue rose 11.1% year-over-year to $1.22 billion, above analysts' expectations of $1.19 billion. With a trailing EPS of $7.55 and a P/E Ratio of 31.43, ResMed's earnings are expected to grow 8.99% next year, from $9.34 to $10.18 per share.

Get ResMed Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ResMed and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

RMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RMD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ResMed Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243$1.59$1.66$1.63
Q2 20243$1.74$1.79$1.77
Q3 20243$1.87$1.92$1.89
Q4 20243$1.92$2.00$1.96
FY 202412$7.12$7.37$7.25
Q1 20252$1.93$2.02$1.98
Q2 20252$2.25$2.29$2.27
Q3 20252$2.28$2.37$2.33
Q4 20252$2.35$2.44$2.40
FY 20258$8.81$9.12$8.97
Q1 20261$2.25$2.25$2.25
Q2 20261$2.33$2.33$2.33
Q3 20261$2.48$2.48$2.48
Q4 20261$2.48$2.48$2.48
FY 20264$9.54$9.54$9.54
Q1 20271$2.45$2.45$2.45

ResMed Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/24/2024Q1 2025$2.03$2.20+$0.17$2.29$1.19B$1.22B
8/1/2024Q4 2024$2.03$2.08+$0.05$2.18$1.22B$1.20B
4/25/2024Q3 2024$1.91$2.13+$0.22$2.22$1.17B$1.20B
1/24/2024Q2 2024$1.81$1.88+$0.07$2.34$1.15B$1.16B
10/26/2023Q1 2024$1.63$1.64+$0.01$1.79$1.10B$1.10B
8/3/2023Q4 2023$1.67$1.60 -$0.07$1.64$1.14B$1.12B
4/27/2023Q3 2023$1.58$1.68+$0.10$1.78$1.05B$1.12B
1/26/2023Q2 2023$1.62$1.66+$0.04$1.79$996.22M$1.03B

ResMed Earnings - Frequently Asked Questions

ResMed (NYSE:RMD) last announced its quarterly earning data on Thursday, October 24, 2024. Learn more on RMD's earnings history.

In the previous quarter, ResMed (NYSE:RMD) reported $2.20 earnings per share (EPS) to beat the analysts' consensus estimate of $2.03 by $0.17. Learn more on analysts' earnings estimate vs. RMD's actual earnings.

The conference call for ResMed's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for ResMed's latest earnings report can be read online.
Read Transcript

ResMed's earnings report can be found in their filing with the SEC.
View SEC filing

ResMed (NYSE:RMD) has a recorded annual revenue of $4.81 billion.

ResMed (NYSE:RMD) has a recorded net income of $1.02 billion. RMD has generated $7.55 earnings per share over the last four quarters.

ResMed (NYSE:RMD) has a trailing price-to-earnings ratio of 31.43 and a forward price-to-earnings ratio of 25.40. The price/earnings-to-growth ratio is 1.73.

ResMed's earnings are expected to grow from $9.34 per share to $10.18 per share in the next year, which is a 8.99% increase.

More Earnings Resources from MarketBeat



This page (NYSE:RMD) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners